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Abstract 
A range of particulate delivery systems have been considered as vaccine adjuvants. Of these 
systems, liposomes offer a range of advantages including versatility and flexibility in design 
format and their ability to incorporate a range of immunomodulators and antigens. Here we 
briefly outline research, from within our laboratories, which focused on the systematic 
evaluation of cationic liposomes as vaccines adjuvants. Our aim was to identify physico-
chemical characteristics that correlate with vaccine efficacy, with particular consideration of 
the interlink between depot-forming action and immune responses. A variety of parameters 
were investigated and over a range of studies we have confirmed that cationic liposomes, 
based on dimethyldioctadecylammonium bromide and trehalose 6,6’-dibehenate formed a 
depot at the injection site, which stimulates recruitment of antigen presenting cells to the 
injection site and promotes strong humoral and cell-mediated immune responses. Physico-
chemical factors which promote a strong vaccine depot include the combination of a high 
cationic charge and electrostatic binding of the antigen to the liposome system and the use of 
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lipids with high transition temperatures, which form rigid bilayer vesicles. Reduction in 
vesicle size of cationic vesicles did not promote enhanced drainage from the injection site. 
However, reducing the cationic nature through substitution of the cationic lipid for a neutral 
lipid, or by masking of the charge using PEGylation, resulted in a reduced depot formation 
and reduced Th1-type immune responses, whilst Th2-type responses were less influenced. 
These studies confirm that the physico-chemical characteristics of particulate-based adjuvants 
play a key role in the modulation of immune responses. 
 
  
3 
 
1. Liposomes as vaccine adjuvants 
Of the range of delivery systems available, liposomes were the first delivery system to be 
described as being able to act as immunological adjuvants.1 Liposomes are composed of lipid 
molecules which, when dispersed into an aqueous phase, form bilayered vesicles (Figure 1). 
These lipid building-blocks are composed of three sections (tail, linker and head) and due to 
the hydrophobic and hydrophilic natures of the tail and head respectively, the water-loving 
head group is directed outwards, thus forming liposomes. Liposomes can be manufactured in 
a wide range of morphologies from single to multi-lamellar in structure and ranging in size 
from ~50 nm up to several microns in size (Figure 1).  
 
Figure 1: Schematic outline of the formation of liposomes. Lipid molecules, when dispersed 
in an aqueous phase form bilayers vesicles that can be prepared in a range of sizes from 
larger multilamellar vesicles, through to small unilamellar vesicles. 
Liposomes are an ideal vaccine delivery system due to their particulate nature, flexibility in 
formulation, ability to incorporate a range of moieties including immunogenic molecules and 
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antigens; it is these parameters that can be used to promote a range of immune responses.2 
The geometry of liposomes is principally determined by their method of manufacturing and 
their lipid composition. For example, size reduction of vesicles can include sonication, high-
shear homogenization or high pressures whereby disruptive energy causes large vesicles to 
rearrange into smaller ones. An overview of a range of liposome production methods are 
shown in Figure 2. However, these traditional methods of liposome synthesis raise several 
difficulties e.g. mechanical stresses, difficultly in up-scaling and methods that rarely lead to 
size-uniform liposomes.3 To address these issues, the area of microfluidics, and its associated 
development of novel lab-on-a-chip based devices, has gainedincreasing attention over recent 
decades. Besides saving time and money, the use of microfluidics methods reduces space and 
sample volume (Figure 3).  
 
Figure 2: Summary of the advantages and disadvantages of some of the common processes 
used in the manufacture of liposomes. 
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Figure 3: Schematic outline of the principles involved in the preparation of liposomes using 
microfluidics. 
 
In terms of developing liposomal adjuvants, a key consideration is their ability to carry and 
delivery their antigen payload to the appropriate target site. Again, a range of methods have 
been investigated to promote or improve antigen and liposome association e.g. the 
dehydration-rehydration.4 A relatively simple and flexible option is to adopt electrostatic 
interactions to support antigen loading, where the liposomes are designed with the 
appropriate surface charge to electrostatically adsorb antigen.5 To exploit this method, the 
overall charge of a peptide or protein must be known; this will be dependent on its amino 
acids and will change according to the pH of the solution it is suspended in. However, most 
protein adjuvants have an overall negative charge making cationic liposomes an appropriate 
design choice. 
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Adopting a cationic change is not just beneficial for enhanced antigen loading; cationic 
systems can also enhance antigen delivery and immunostimulatory potency. For example, the 
cationic lipid dimethyldioctadecylammonium (DDA) was discovered as an adjuvant by Gall 
in the mid-1960s.6 DDA is a synthetic amphiphile, which contains a quaternary ammonium 
group with two 18-carbon-long alkyl chains forming the hydrophobic moiety and two methyl 
groups, which together with the ammonium group form the polar head group (Figure 4). The 
positively charged head group carries a monovalent counterion, typically bromide or 
chloride. Due to its amphiphilic character, DDA can form liposomal structures when 
dispersed in aqueous media at temperatures above its gel-to-liquid phase transition 
temperature (~47oC).7 DDA is known to induce cell-mediated immunity and delayed-type 
hypersensitivity8 and, along with its cationic nature and surfactant properties, has been shown 
to be an effective adjuvant in numerous applications, including mucosal immunization9, gene 
delivery10,11 and subunit vaccine delivery.12-15  
 
Figure 4: Liposomal adjuvants can be prepared from a range of lipids, for example the 
cationic lipid Dimethyldioctadecylammonium bromide and D-(+)- trehalose 6,6’-dibehenate. 
Combined together, these lipids from liposomes with strong adjuvant properties. 
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The mechanism of action behind the adjuvant effect of DDA has been attributed to its 
positive surface charge and its ability to associate antigens.16 This was confirmed and further 
elaborated by using ovalbumin (OVA) as a model antigen.17 Stimulation of immature bone 
marrow-derived dendritic cells (BMDCs) with fluorescently labeled OVA showed that 
adsorption of OVA onto DDA enhanced the cellular acquisition of the antigen. Further, 
inhibition of active cellular processes by OVA stimulation at 4°C or by the addition of 
cytochalasin D reduced the cellular uptake, suggesting that active actin-dependent 
endocytosis is the predominant uptake mechanism.17 DDA-mediated OVA uptake was also 
associated with a functional enhancement of the APCs. This was shown by measuring the 
increase in gamma interferon (IFNγ) production and cellular proliferation of purified 
autologous DO11.10 T-cells transgenic for a T-cell receptor recognizing a major 
histocompatibility complex (MHC) class II–restricted OVA-epitope (OVA323-339). Both 
proliferation and IFNγ production was increased upon interaction with either murine BMDCs 
or purified B-cells, stimulated with OVA adsorbed to DDA.17,18  
To further enhance the potency of DDA liposomes, a second component, D-(+)-trehalose 
6,6’-dibehenate (TDB) can be added.13 TDB is a synthetic analog of trehalose-6,6-
dimycolate, a immunostimulatory component of Mycobacterium tuberculosis. TDB has two 
saturated fatty-acid chains of 22 carbons (behenyl), each replacing the branched 
mycobacterial mycolic acids of >70 carbons (Figure 4). These two behenyl chains are linked 
by ester bonds to carbon number 6 of each of the two glucopyranose rings making up the 
trehalose head group (Figure 4). TDB has been shown to retain much of the bioactivity of the 
native form, whilst showing less toxicity as a result of the shorter fatty acid chains.19,20 
Combination with DDA it is an efficient adjuvant for TB subunit vaccines,13 inducing a 
strong IFNγ response, considered to be the key cytokine for induction of a Th1 immune 
response and essential for effective anti-mycobacterial immunity.21,22 
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Interestingly TDB does not only enhance the immunogenicity of the DDA liposomal 
systems.7 Having shown that DDA:TDB could be effectively prepared in a sterile and stabile 
format via lyophilization and gamma-sterilization,23,24 the contributing role of TDB to the 
DDA membranes both in an aqueous25 and freeze-dried format26 was shown to result from 
the higher attractive forces between the trehalose head group of TDB and water compared to 
the quaternary ammonium head group of DDA and water.25  
 
2. Antigen delivery and immune-stimulation 
Mycobacteria are well known to exert a number of immunostimulatory effects and are a good 
source of adjuvants e.g. Freund’s complete adjuvant (an oil emulsion and heat killed 
mycobacteria). Purified components of mycobacteria such as TDB have also been shown to 
be effective. Holten-Andersen et al.13 first investigated the combination of DDA:TDB, and 
studied the ability of seven different immunostimulators, including four mycobacteria-
derived immunostimulators, to increase the protective efficacy of DDA, using ESAT-6 as a 
possible TB antigen. An effective IFNγ response was obtained with the combination of DDA 
with monophosphoryl lipid A (MPL) and/or TDB. This combination also induced protection 
in mice similar to that obtained after BCG vaccination. The protective efficacy of DDA:TDB 
using Ag85B-ESAT-6 was also shown7 and the adjuvant activity of DDA:TDB was 
compared to aluminium hydroxide. These studies showed that immunization with DDA:TDB 
leads to high levels of IFNγ secretion and low levels of interleukin-5 (IL-5) secretion by 
CD4+ T-cells, whereas aluminium hydroxide immunized mice exhibited the opposite pattern, 
with a negligible IFNγ secretion and higher levels of IL-5 secretion.7 The DDA:TDB-
adjuvated vaccine resulted in the same high levels of IgG1 antibody titers, as seen after 
immunization with the aluminium hydroxide-adjuvated vaccine, whereas the level of IgG2 
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antibodies were significantly higher after immunization using DDA:TDB as an adjuvant, 
compared to aluminium hydroxide.7,27 Additionally, studies have shown that DDA:TDB 
induces a CD4+ T-cell population, predominantly tumor necrosis factor-alpha (TNF-α)+, IL-
2+, IFNγ+, TNF-α+ and IL-2+ multifunctional T-cells, which are long-lived and maintained for 
at least 1 year in mice.28 
In terms of its mechanism of action, the C-type lectin receptor Mincle, expressed in 
macrophages, is upregulated in the presence of TDM and TDB and triggers the FcRγ-Syk-
Card9 pathway. The activation of macrophages by TDB/TDM depends on FcRγ, which 
represents the Sky-coupling adapter protein. Deletion of the FcRγ protein resulted in loss of 
transcriptional responses to TDB/TDM.29 The Syk-Card9 pathway is crucial for antigen-
presenting cell activation in vitro and for the adjuvanticity of TDB/TDM in vivo.30,31 The 
glycolipids TDM and TDB are Mincle-recognized ligands. Molecular mechanisms of 
TDB/TDM adjuvanticity were identified to be strictly Mincle-dependent and strong IL-17 
production post immunization controls the generation of cellular immunity.31,32 Desel et al.32 
showed that adjuvanticity of TDM/TDB not only depends on Mincle, but also necessitates 
MyD88. Whereas in vitro studies identified MyD88 independence, in vivo adjuvanticity was 
strongly dependent on MyD88 signaling. Immunization experiments included DDA/TDB and 
H1 subunit vaccine for TB, composed of Ag85B and ESAT-6. Mincle and MyD88 were 
shown to be indispensable prerequisite for antigen-specific Th1 and Th17 immune responses 
in vivo supported by IL-1/IL-1R1 signaling.32  
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3. Systematically investigating the formulation parameters controlling the efficacy of 
DDA:TDB as a liposomal adjuvant 
Building on the demonstrated potential of the DDA/TDB system developed by the Staten 
Serum Institut (e.g. reference 13), a series of collaborative studies were undertaken to 
investigate the principles behind the efficacy of this formulation, with one focus being 
consideration of physico-chemical attributes. Our aim was to identify formulation attributes 
that could be considered to act as correlates for efficacy. These investigations were based on 
early studies7 which investigated the incorporation of TDB into DDA liposomes and 
considering the method of liposome preparation and TDB content. These studies 
demonstrated that incorporation of TDB into DDA liposome bilayers had no impact on 
antigen loading; however, increasing the TDB concentration (0 to 20 mol%) reduced the 
transition temperature of the bilayers from 47 to 42oC. The TDB concentration also impacted 
on immune response. Whilst all the DDA liposome formulations were able to induce high 
levels of IFNγ, the formulation containing 11% TDB gave the highest responses in terms of 
IFNγ, IgG1 and IgG2b antigen specific responses in C57B1/6j mice. In comparison to Alum, 
IFNγ responses from blood lymphocytes isolated from immunized mice were significantly 
higher for DDA:TDB (11%), whilst IL-5 levels were significantly lower. In addition to 
potentiating the immune response of DDA liposomes, incorporation of TDB within the 
formulation was shown to effectively stabilize the DDA liposomes.7 Given that this 
DDA:TDB combination was shown to be highly effective, this combination was also 
incorporated into a range of other particulate based systems including niosomes33 and 
microspheres.34,35 Incorporation of DDA and TDB within either of these systems did not 
produce particulates with enhanced adjuvant properties compared to the liposomal 
DDA:TDB liposome formulation. Therefore, the next stage was to focus on the DDA:TDB 
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liposome formulation and consider the role of its physico-chemical characteristics in it 
performance as an adjuvant, with particular reference to it biodistribution.  
3.1 The impact of lipid choice – the controlling role of charge 
The highly cationic nature of the DDA:TDB liposome formulation offers the advantage of 
these systems being able to electrostatically bind a range of antigens; however, we also 
proposed the hypothesis that this cationic charge would influence the biodistribution of the 
vesicles and their adsorbed antigen. Therefore, we undertook a range of studies applying a 
relatively simple, effective and reproducible method to follow the biodistribution of the 
liposomes and their associated antigen using a dual-radiolabeling method developed within 
our laboratories, where the liposomes are labeled with 3H and the antigen with 125I.36 Using 
this method we were able to demonstrate that whilst antigen delivered without liposomes 
were removed quickly from the body, liposomes based on DDA promoted a depot at the 
injection site (both after sub-cutaneous or intramuscular injection) and that TDB did not 
significantly influence this deport effect.37 However, the presence of TDB in the DDA 
liposomes increased the influx of monocytes to the site of injection, and the subsequent 
draining of the liposomal adjuvant to the popliteal lymph nodes, in addition to inducing a 
powerful Th1 response.37  
The impact on vesicle charge on the deposition of antigen at the injection site was further 
considered by comparing cationic DDA:TDB liposomes with a comparable near-neutral 
liposome formulation composed of Distearoylphosphatidylcholine (DSPC) and TDB (11 
mol%).38 This study demonstrates that the cationic nature of the vesicles promotes the 
retention of the liposomal components at the site of injection, with the DSPC:TDB 
formulation being more rapidly cleared. Furthermore, the electrostatic adsorption of antigen 
to the vesicles was demonstrated to be a key requirement for antigen retention. Not only did 
the neutral liposomes give poor antigen absorption and retention at the injection site, cationic 
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liposomes which were unable to absorb a cationic model antigen (as would be expected) also 
failed to promote an antigen depot, despite the liposomes being retained at the injection site.38 
However, distearoylphosphatidylcholine-based liposomes entrapping antigen within the 
vesicles were shown to offer a potential alternative to cationic-based systems, especially for 
the delivery of zwitterionic or cationic molecules.39  
3.2 Choosing the cationic lipid component 
Given that we had demonstrated the controlling role of the cationic lipid in the promotion of a 
depot at the site of injection, the next consideration addressed whether this was applicable to 
a range of cationic formulations. Therefore the ability of 3β-[N-(N′,N′-
dimethylaminoethane)carbomyl] cholesterol (DC-Chol), 1,2-dioleoyl-3-trimethylammonium 
propane (DOTAP), or DDA liposomes incorporating immunomodulating trehalose 
dibehenate (TDB) to form an antigen depot at the site of injection (SOI) and to induce 
immunological recall responses against co-administered tuberculosis vaccine antigen was 
investigated.40 Despite all three formulations being cationic in nature, differences in the 
biodistribution of these vesicles were noted, with the DOTAP formulation draining more 
rapidly from the injection site compared to the DDA or DC-Chol formulations. This was 
reflected in a slower drainage to the local lymphoid tissue. This was attributed to the DOTAP 
liposomes having a lower transition temperature and therefore more fluid in nature, thus 
promoting easier drainage from the injection site. This was confirmed by comparing 
liposomes prepared using DDA with liposomes prepared with its unsaturated analog 
dimethyldioleoylammonium bromide (DODA), which contained one unsaturated C=C bound 
in each of the lipophilic acyl chains. By comparing the delivery properties of liposomes 
prepared using these two lipids, liposomes which were rigid (DDA:TDB liposomes) or fluid 
(DODA:TDB liposomes) in nature at physiological temperatures could be considered.41 
Through a series of studies it was shown that these two different formulations showed major 
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differences in their ability to drive a Th1 immune response. The rigid DDA-based liposomes 
retained higher levels of antigen at the injection site, resulting in a continuous attraction of 
antigen-presenting cells that expressed elevated levels of the co-stimulatory molecules CD40 
and CD86.41 Overall the rigid, DDA-liposomes induced 100-fold higher Th1 responses than 
the fluid DODA liposome counterparts, confirming that a range of physico-chemical 
properties have a major influence on the efficacy of liposomal adjuvants. 
3.3.Enhancing delivery of DDA:TDB to the target site 
While all the studies undertaken with the DDA:TDB had proved it gave strong Th1 responses 
and formed a strong depot at the site of injection, this did not necessarily demonstrate a direct 
correlation between the these two attributes, and enhancing the delivery of DDA:TDB+ 
antigen to APC should further boost its potency. This was nicely demonstrated by a study led 
by Johansen’s group42, where the immune responses achieved by DDA:TDB when 
administered via the sub-cutaneous, intradermal, intramuscular or intra-lymphatic routes. 
This study showed that the route of administration promoted no notable differences in IgG1. 
However, the administration route had a major influence on Th1 responses; intra-lymphatic 
injection gave strong early IgG2a responses and significantly higher IFNγ secretion from 
splenocytes collected from immunized mice via this route compared to the other routes.42 
This suggested that while the highly effective DDA:TDB liposome formulation formed a 
strong depot effect at the injection site, trafficking of this formulation to the draining 
lymphatics would enhance vaccine efficacy. 
3.3.1 The role of particulate size in the biodistribution of DDA:TDB liposomal 
adjuvants 
When considering the biodistribution of liposomes, size is often shown to have a significant 
impact. Hence, liposome size was also an important attribute to consider. In the above studies 
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the DDA:TDB liposomes studied were around 500 - 600 nm in size, therefore consideration 
of the impact of the size of the DDA:TDB vesicles on their role as adjuvants was also 
investigated.43 DDA:TDB liposomes were prepared in the following size ranges: small (<200 
nm), medium (500-600 nm), and large (~1500 nm). No significant difference in the drainage 
of the liposomes or their adsorbed antigen from the site of injection was seen between the 
different sized liposomes. However, significantly higher levels (but still relatively low 
amounts of the total dose) of the smaller liposomes were noted at the popliteal lymph node, 6 
hours after injection.43 This was shown to be independent to cellular phagocytosis, as 
macrophage uptake of these various liposomes was not shown to be size-dependent.43 This 
would suggest that due to their cationic nature, and independent of their size, the vesicles 
aggregate after administration, due to interaction with interstitial proteins which are generally 
anionic in nature, thus prohibiting their clearance from the site of injection.  
3.3.2 Retaining the DDA component but masking its cationic nature – pegylated 
DDA:TDB 
Given that the depot effect had been shown to be primarily due to the cationic nature of the 
vesicles, which results in electrostatic adsorption of the antigen and aggregation of the 
vesicles at the site of injection, a second method to promote drainage (yet retain the DDA 
content of the DDA:TDB:antigen formulation) to the lymphatics was considered. A series of 
studies were undertaken where the cationic DDA component of the liposomes was retained, 
yet the cationic nature masked with polyethylene glycol. Polyethylene glycol (PEG) is the 
most widely used hydrophilic polymer for the steric stabilization of liposome drug delivery 
systems. It is a linear polyether diol with many useful properties, including the ability to be 
conjugated to a liposomal surface to create a steric, hydrophilic barrier which can enhance 
increasing half-life of the liposomes, through steric stabilization.44 Coating of liposomes with 
PEG (often referred to as PEGylation), is exploited in therapeutic products such as Caelyx, 
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which is a PEGylated liposomal delivery system for doxorubicin. PEG can be incorporated 
onto the surface of liposomes in different ways, but the most widely used method at present is 
to anchor the polymer in the liposomal membrane via a cross-linked lipid (i.e. PEG-
distearoylphosphatidylethanolamine [DSPE]). 
DDA:TDB liposomes were prepared with increasing PEG concentrations (0 to 25 mol%). 
This resulted in the cationic zeta potential of the vesicles dropping from ~55 mV for 
DDA:TDB down to 39 mV with the addition of 10% PEG, and to 3 mV when 25% PEG was 
added.45 This drop in zeta potential results in a reduction in both the liposome and antigen 
depot at the injection site, and reduced monocyte influx to the injection site. However, whilst 
PEGylation of DDA:TDB tended to promote an increased drainage of liposomes to the local 
lymph node, this did not translate to an increased antigen delivery to the draining lymph 
nodes.45 In terms of immune responses, whilst increasing PEG concentrations in the 
DDA:TDB liposomal adjuvant made no significant difference in IgG1 responses, both IgG2b 
and IFNγ responses reduced with increasing PEG concentrations.45 This suggested that 
PEGylation was able to block the formation at the site of injection, yet the PEGylated 
liposomes were less able to carry the antigen with them to the draining lymph nodes.  
In an attempt to address this and improve co-delivery of the liposomes and antigen to the 
draining lymph nodes, a second series of PEGylated liposomes were prepared where the 
antigen was incorporated within the liposomes rather than surface adsorbed.45 However, this 
did not significantly enhance antigen delivery to the PLN, nor change the immune-responses 
compared to the DDA:TDB formulations with the surface-adsorbed antigen.45 To consider if 
a combination of size reduction and PEGylation of the vesicles could further modify the 
clearance kinetics of these liposomal adjuvants, DDA:TDB liposomes with and without 
PEGylation were also prepared as small unilamellar vesicles (SUV).46 By using 
DDA:TDB:10% PEG vesicles which were ~150 nm in size, both liposome and antigen dose 
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at the popliteal lymph node 4 days after injection was increased and earlier antibody 
responses noted.46  
The ability of PEGylation of small cationic liposomes to enhance drainage was also 
demonstrated with DNA vaccine carriers. Liposomes composed of phosphtidylcholine, 
dioleoylphosphatidylethanolamine and the cationic lipid DOTAP were prepared with 
entrapped OVA-encoding plasmid DNA; the introduction of PEG onto the surface of these 
small cationic vesicles resulted in enhanced lymphatic drainage after sub-cutaneous injection, 
but the immune responses measured were not improved when compared to non-PEGylated 
liposomes.47  
3.4 The controlling role of the adjuvant depot on Th1 but not Th2 responses 
A particular reference point in the above outlined studies was the ability of the liposomal 
formulation to form a depot at the site of injection and the overall design factors identified to 
control the formation of a depot at the site of injection for liposomal adjuvants are 
summarised in Figure 5 Until recently, it had been widely accepted that the activity of alum-
based adjuvants was attributed to its ability to retain the antigen at the site of injection.48 This 
theory was recently put into question through various studies which demonstrated that alum 
with non-adsorbed or adsorbed antigen gave rise to similar antibody responses49,50 and indeed 
removal of the alum injection site did not influence the subsequent immune response.51  
Through the above series of studies, we have systematically considered the correlation 
between the induction of immune responses and the ability of the liposomal formulation to 
promote depot formation. These studies demonstrate that 1) liposomes that promote a strong 
depot effect also potentiate a strong Th1 response, and 2) Th2 responses generated by these 
liposomal adjuvants were not influenced by/reliant upon the depot formation. These findings 
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are in line with the more recent understanding of Alum’s adjuvant action, which 
predominately drives a Th2 response and appears to act independent of a depot.49-51  
 
Figure 5: Formulation parameters shown to impact on the formation of a DDA:TDB 
liposome depot at the injection site and a summary of the impact this has on immune 
responses. 
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Figure legends 
Figure 1: Schematic outline of the formation of liposomes. Lipid molecules, when dispersed 
in an aqueous phase form bilayers vesicles which can be prepared in a range of sizes from 
larger multilamellar vesicles, through to small unilamellar vesicles. 
Figure 2: Summary of the advantages and disadvantages of some of the common processes 
used in the manufacture of liposomes. 
Figure 3: Schematic outline of the principles involved in the preparation of liposomes using 
microfluidics. 
Figure 4: Liposomal adjuvants can be prepared from a range of lipids, for example the 
cationic lipid Dimethyldioctadecylammonium bromide and D-(+)- trehalose 6,6’-dibehenate. 
Combined together, these lipids from liposomes with strong adjuvant properties. 
Figure 5: Formulation parameters shown to impact on the formation of a DDA:TDB 
liposome depot at the injection site and a summary of the impact this has on immune 
responses. 
